Interstitial lung disease during chemotherapy combined with oxaliplatin and/or bevacizumab in advanced colorectal cancer patients

Japanese Journal of Clinical Oncology

Volumn 41, Issue 4, 2011, Pages 498-502

  Usui, Kazuhiro ^a   Katou, Yuu ^a   Furushima, Kaoru ^a   Tanaka, Yoshiaki ^a   Tanai, Chiharu ^a   Ishihara, Teruo ^a  

^a Kanto Teishin Hospital   (Japan)

Author keywords

Bevacizumab; Colorectal cancer; Drug induced pneumonitis; Interstitial lung disease; Oxaliplatin

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CYCLOSPORIN A; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METHYLPREDNISOLONE; OXALIPLATIN; PANITUMUMAB; PREDNISOLONE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CASE REPORT; CLINICAL FEATURE; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG FIBROSIS; LUNG FUNCTION TEST; MALE; MULTIPLE CYCLE TREATMENT; SMOKING;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ALVEOLITIS, EXTRINSIC ALLERGIC; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FLUOROURACIL; HUMANS; JAPAN; LEUCOVORIN; LUNG DISEASES, INTERSTITIAL; MALE; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PULMONARY FIBROSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SMOKING; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79953735073     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyr006     Document Type: Article

References (23)

1. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47.
2. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
3. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A Randomized GERCOR Study. J Clin Oncol 2004;22:229-37.
4. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-7.
5. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatinbased chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase study. J Clin Oncol 2008;26:2013-9.
6. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007;25:4779-86.
7. Fuchs CS, Marshall J, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol 2008;26:689-90.
8. Shimura T, Fuse N, Yoshino T, Minashi K, Tahara M, Doi T, et al. Clinical features of interstitial lung disease induced by standard chemotherapy (FOLFOX or FOLFIRI) for colorectal cancer. Ann Oncol 2010;21:2005-10.
9. Tamura J, Nakauchi M, Nakayama Y, Kitaguchi K, Sakikubo M, Ura K, et al. A case of interstitial pneumonitis induced by FOLFIRI + bevacizumab combination therapy for liver and lung metastasis of colon cancer. Gan To Kagaku Ryoho 2009;36:2665-8 (in Japanese).
10. Kudoh S, Kato H, Nishiwaki Y, Fukuoka M, Nakata K, Ichinose Y, et al. Interstitial lung disease in Japanese patients with lung cancer. Am J Crit Care Med 2008;177:1348-57.
11. American Thoracic Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS Board of Directors, June 2001 and by The ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002;165:277-304.
12. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 2004;22:2184-91.
13. Herbst RS, Sandler AB. Non-small cell lung cancer and antioangiogenic therapy: what can be expected of bevacizumab? Oncologist 2004;9(Suppl 1):19-26.
14. Mu{double acute}ller NL, White DA, Jiang H, Gemma A. Diagnosis and management of drug-associated interstitial lung disease. Br J Cancer 2004;91(Suppl 2):S24-30.
15. Thickett DR, Armstrong L, Christie SJ, Millar AB. Vascular endothelial growth factor may contribute to increased vascular permeability in acute respiratory distress syndrome. Am J Respir Crit Care Med 2001;164:1601-5.
16. Thickett DR, Armstrong L, Millar AB. A role for vascular endothelial growth factor in acute and resolving lung injury. Am J Respir Crit Care Med 2002;166:1332-7.
17. Maitre B, Boussat S, Jean D, Gouge M, Brochard L, Housset B, et al. Vascular endothelial growth factor synthesis in the acute phase of experimental and clinical lung injury. Eur Respir J 2001;18:100-6.
18. The Japanese Respiratory Society. Idiopathic Interstitial Pneumonias: Diagnosis and Treatment. Tokyo: The Japanese Respiratory Society. Nankodo 2004;36-40 (in Japanese).
19. Kondoh Y, Taniguchi H, Kawabata Y, Yokoi T, Suzuki K, Takagi K. Acute exacerbation in idiopathic pulmonary fibrosis: analysis of clinical and pathologic findings in three cases. Chest 1993;103:1808-12.
20. Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE Jr, et al. Idiopathic pulmonary fibrosis clinical research network investigators. acute exacerbation in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007;176:636-43.
21. Inase N, Sawada M, Ohtani Y, Miyake S, Isogai S, Sakashita H, et al. Cyclosporin A followed by the treatment of acute exacerbation of idiopathic pulmonary fibrosis with corticosteroid. Intern Med 2003;42:565-70.
22. Homma S, Sakamoto S, Kawabata M, Kishi K, Tsuboi E, Motoi N, et al. Cyclosporin treatment in steroid-resistant and acutely exacerbated interstitial pneumonia. Intern Med 2005;44:1144-50.
23. Sakamoto S, Homma S, Miyamoto A, Kurosaki A, Fujii T, Yoshimura K. Cyclosporin A in the treatment of acute exacerbation of idiopathic pulmonary fibrosis. Intern Med 2010;49:109-15.